Skip to main content

Advertisement

SpringerLink
Log in

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

  • Correspondence
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337. https://doi.org/10.1093/neuonc/nox078

    Article  PubMed  PubMed Central  Google Scholar 

  2. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132

    Article  PubMed  Google Scholar 

  3. Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79. https://doi.org/10.1186/s40478-016-0351-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/nejmoa1402121

    Article  Google Scholar 

  5. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW et al (2013) BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 31:e233–e236. https://doi.org/10.1200/JCO.2012.46.0220

    Article  PubMed  Google Scholar 

  8. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718. https://doi.org/10.1007/s00401-010-0781-z

    Article  PubMed  Google Scholar 

  10. Hasselblatt M, Jaber M, Reuss D, Grauer O, Bibo A, Terwey S et al (2018) Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. J Neuropathol Exp Neurol 77:422–425. https://doi.org/10.1093/jnen/nly012

    Article  PubMed  Google Scholar 

  11. Hirose Y, Sasaki H, Abe M, Hattori N, Adachi K, Nishiyama Y et al (2013) Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathol 30:203–208. https://doi.org/10.1007/s10014-013-0148-y

    Article  CAS  PubMed  Google Scholar 

  12. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915. https://doi.org/10.1007/s00401-013-1195-5

    Article  CAS  PubMed  Google Scholar 

  13. Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131:137–146. https://doi.org/10.1007/s00401-015-1493-1

    Article  CAS  PubMed  Google Scholar 

  14. Lee M, Kang SY, Suh YL (2018) Genetic alterations of epidermal growth factor receptor in glioblastoma: the usefulness of immunohistochemistry. Appl Immunohistochem Mol Morphol. https://doi.org/10.1097/pai.0000000000000669

    Article  PubMed  Google Scholar 

  15. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133:1–3. https://doi.org/10.1007/s00401-016-1646-x

    Article  PubMed  Google Scholar 

  16. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C et al (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 27:851–852. https://doi.org/10.1111/bpa.12457

    Article  PubMed  Google Scholar 

  17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system. Intl. Agency for Research, City

    Google Scholar 

  18. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429–435. https://doi.org/10.1111/bpa.12171

    Article  PubMed  Google Scholar 

  19. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  20. Louis DN, von Deimling A (2017) Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zulch, the WHO… and Shakespeare. Acta Neuropathol 134:517–520. https://doi.org/10.1007/s00401-017-1765-z

    Article  PubMed  Google Scholar 

  21. Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B et al (2017) Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol 19:394–404. https://doi.org/10.1093/neuonc/now189

    Article  PubMed  Google Scholar 

  22. Nomura M, Mukasa A, Nagae G, Yamamoto S, Tatsuno K, Ueda H et al (2017) Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol 134:941–956. https://doi.org/10.1007/s00401-017-1771-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Picart T, Barritault M, Berthillier J, Meyronet D, Vasiljevic A, Frappaz D et al (2018) Characteristics of cerebellar glioblastomas in adults. J Neurooncol 136:555–563. https://doi.org/10.1007/s11060-017-2682-7

    Article  PubMed  Google Scholar 

  24. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD et al (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131:833–845. https://doi.org/10.1007/s00401-016-1539-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE et al (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136:273–291. https://doi.org/10.1007/s00401-018-1837-8

    Article  CAS  PubMed  Google Scholar 

  26. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417. https://doi.org/10.1007/s00401-015-1454-8

    Article  CAS  PubMed  Google Scholar 

  27. Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M et al (2018) Distribution of EGFR amplification, combined 7gain and 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol (in press), Doi. https://doi.org/10.1007/s00401-018-1905-0

    Book  Google Scholar 

  28. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. https://doi.org/10.1016/j.ccr.2012.08.024

    Article  CAS  PubMed  Google Scholar 

  29. Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A et al (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634. https://doi.org/10.1007/s00401-016-1611-8

    Article  PubMed  Google Scholar 

  30. Vaubel RA, Caron AA, Yamada S, Decker PA, Eckel Passow JE, Rodriguez FJ et al (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172–182. https://doi.org/10.1111/bpa.12495

    Article  CAS  PubMed  Google Scholar 

  31. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V et al (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185. https://doi.org/10.1038/ncomms3185

    Article  CAS  PubMed  Google Scholar 

  32. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. https://doi.org/10.1007/s00401-015-1409-0

    Article  CAS  PubMed  Google Scholar 

  33. Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959. https://doi.org/10.1007/s00401-017-1781-z

    Article  CAS  PubMed  Google Scholar 

  34. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This paper has been reviewed by the Steering Committee and Clinical Advisory Panel of cIMPACT-NOW [15, 16] and by the International Society of Neuropathology Executive.

Author information

Authors and Affiliations

  1. Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA

    Daniel J. Brat

  2. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    Kenneth Aldape

  3. Department of Neurosurgery, Huntsman Cancer Center, University of Utah, Salt Lake City, UT, USA

    Howard Colman

  4. Department of Neurosurgery, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA

    Eric C. Holland

  5. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    David N. Louis

  6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Robert B. Jenkins

  7. Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA

    B. K. Kleinschmidt-DeMasters

  8. Department of Pathology, University of California San Francisco, San Francisco, CA, USA

    Arie Perry

  9. Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany

    Guido Reifenberger

  10. German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Düsseldorf, Germany

    Guido Reifenberger

  11. Malnati Brain Tumor Institute, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Roger Stupp

  12. Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany

    Andreas von Deimling

  13. Clinical Cooperation Unit Neuropathology, German Cancer Institute (DKFZ), Heidelberg, Germany

    Andreas von Deimling

  14. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

    Michael Weller

Authors
  1. Daniel J. Brat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Aldape
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard Colman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric C. Holland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David N. Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert B. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. K. Kleinschmidt-DeMasters
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Arie Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guido Reifenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Roger Stupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Andreas von Deimling
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Brat.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brat, D.J., Aldape, K., Colman, H. et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136, 805–810 (2018). https://doi.org/10.1007/s00401-018-1913-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-018-1913-0

Search

Navigation